Related Experiment Videos
[Systemic therapy of hemangioma].
1Kinderklinik und Kinderpoliklinik im Dr. v. Haunerschen Kinderspital, Lindwurmstrasse 4, 80337 München.
Kongressband. Deutsche Gesellschaft Fur Chirurgie. Kongress
|February 5, 2002
Summary
Systemic cortisone and interferon are effective treatments for severe hemangiomas, with 80-90% response rates. However, careful consideration of potential severe side effects, like interferon-induced neurotoxicity, is crucial.
Area of Science:
- Pediatric Oncology
- Dermatology
- Pharmacology
Context:
- Life-threatening hemangiomas often lack feasible surgical or laser treatment options.
- Systemic therapies are the primary alternative for complex cases.
Purpose:
- To evaluate the efficacy and risks of systemic cortisone and interferon for treating severe hemangiomas.
- To highlight the critical need for risk-benefit assessment in treatment decisions.
Summary:
- Cortisone and interferon demonstrate comparable efficacy (80-90% response rates) in treating severe hemangiomas.
- Both systemic treatments carry risks of severe side effects, notably neurotoxicity associated with interferon.
- Careful patient selection and risk-benefit analysis are essential for initiating systemic therapy.
Impact:
- Provides evidence for informed clinical decision-making in managing difficult-to-treat hemangiomas.
- Emphasizes the importance of monitoring for and managing adverse events during systemic therapy.
- Contributes to optimizing treatment strategies for pediatric vascular anomalies.